In a real-world study of 83,825 obesity patients and 598,803 T2D patients, semaglutide was associated with 50-56% lower risk for both new and recurring alcohol use disorder compared to other anti-obesity medications, consistent across gender, age, and race.
50-56% lower AUD riskfor both incidence and recurrence, vs. other anti-obesity medications, consistent across gender, age, race, and diabetes status in 83,825 obesity patients + 598,803 T2D patients
What the researchers found
Semaglutide was associated with 50-56% lower risk for both incidence and recurrence of alcohol use disorder compared to other anti-obesity medications, consistent across demographic subgroups and replicated in a T2D cohort.
Why it matters
Alcohol use disorder is a top-10 global cause of disease burden with limited effective treatments. If semaglutide genuinely reduces alcohol use, it could fill an enormous therapeutic gap — especially since it's already widely prescribed for diabetes and obesity, meaning the safety profile is well-established and access infrastructure exists.
The numbers in context
83,825 patients with obesity; 50-56% lower risk for both incidence and recurrence of alcohol use disorders; compared to other anti-obesity medications.
How the study worked
Retrospective cohort study using electronic health records. Primary cohort: 83,825 obesity patients. Replication cohort: 598,803 T2D patients. Compared semaglutide vs. other anti-obesity medications. Outcomes: AUD incidence and recurrence over 12-month follow-up. Stratified by gender, age, race, and diabetes status.
Who was studied
Patients with obesity in real-world electronic health records
What this study cannot tell us
Retrospective observational study — cannot prove causation. Potential confounders include differences in health-seeking behavior between semaglutide and comparator users. AUD diagnosis depends on clinical recognition, which may be inconsistent. No data on actual alcohol consumption amounts. Medication adherence not assessed. Self-reported desire to drink was not measured.
How to read the evidence
Moderate — large retrospective cohort study with replication in an independent cohort. Strong associations but observational design cannot establish causation. Randomized trials needed for definitive evidence.
When this study was published
Published in 2024, among the first large-scale real-world evidence studies examining semaglutide's association with alcohol use disorder.
The bigger picture
Semaglutide's potential effects on addictive behaviors represent one of the most surprising developments in GLP-1 agonist research. GLP-1 receptors are expressed in brain reward circuits, and preclinical studies show GLP-1 agonists reduce alcohol intake in animals. This large real-world study adds substantial human evidence that the brain-reward effects are clinically meaningful. Combined with similar findings for tobacco, this suggests GLP-1 agonists may broadly modulate addictive behaviors.
Questions still open
- Does semaglutide reduce actual alcohol consumption, or does it just reduce the likelihood of being diagnosed with AUD?
- What is the mechanism — does GLP-1 receptor activation in brain reward circuits reduce the reinforcing effects of alcohol?
- Would semaglutide be effective as a primary treatment for AUD in patients without obesity or diabetes?
Common questions
Could semaglutide help people quit drinking?
Should people take semaglutide to reduce drinking?
Read the original research
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.
Nature communications, 15(1), 4548
Citation
Wang, William; Volkow, Nora D; Berger, Nathan A; Davis, Pamela B; Kaelber, David C; Xu, Rong. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.. Nature communications, 15(1), 4548. https://doi.org/10.1038/s41467-024-48780-6